Risk factors for non-skin cancer de novo malignancy (DNM) after lung transplantation have yet to be identified. We queried the United Network for Organ Sharing database for all adult lung transplant patients between 1989 and 2012. Standardized incidence ratios (SIRs) were computed by comparing the data to Surveillance, Epidemiology, and End Results Program data after excluding skin squamous/basal cell carcinomas. We identified 18 093 adult lung transplant patients; median follow-up time was 1086 days (interquartile range 436-2070). DNMs occurred in 1306 patients, with incidences of 1.4%, 4.6%, and 7.9% at 1, 3, and 5 years, respectively. The overall cancer incidence was elevated compared with that of the general US population (SIR 3.26, 95% confidence interval [CI]: 2.95-3.60). The most common cancer types were lung cancer (26.2% of all malignancies, SIR 6.49, 95% CI: 5.04-8.45) and lymphoproliferative disease (20.0%, SIR 14.14, 95% CI: 9.45-22.04). Predictors of DNM following lung transplantation were age (hazard ratio [HR] 1.03, 95% CI: 1.02-1.05, p < 0.001), male gender (HR 1.20, 95% CI: 1.02-1.42, p = 0.03), disease etiology (not cystic fibrosis, idiopathic pulmonary fibrosis or interstitial lung disease, HR 0.59, 95% CI 0.37-0.97, p = 0.04) and single-lung transplantation (HR 1.64, 95% CI: 1.34-2.01, p < 0.001). Significant interactions between donor or recipient smoking and single-lung transplantation were noted. On multivariable survival analysis, DNMs were associated with an increased risk of mortality (HR 1.44, 95% CI: 1.10-1.88, p = 0.009).
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Introduction
Solid organ transplant recipients are known to be at increased risk of a variety of cancers following transplantation. The need for immunosuppression and its attendant increased risks of infection, including viral infections that can predispose to cancer, as well as suppression of innate antitumor surveillance activity have all been postulated to contribute to this increase (1) . Patients receiving heart, lung, kidney, or liver transplants appear to be at particularly elevated risk. Standardized incidence ratios (SIRs), which compare a population of interest to a standardized American population to estimate excess cancer incidences, average 2.10 for all cancer types, with particularly elevated SIRs typically seen for non-Hodgkin's lymphoma, lung, livery, and renal cancers (2) .
Though survival following lung transplantation continues to improve, to date, no study has carefully examined risk factors for de novo malignancy (DNM) specifically following orthotopic lung transplantation (OLT) or assessed its impact on survival following transplantation (3) . Accordingly, we examined a large registry of transplant patients to identify risk factors for DNMs following lung transplantation and to assess whether the development of DNM was an independent predictor of decreased survival.
Methods

Patient population
We conducted an institutional review board (IRB)-approved review of the records of all patients undergoing isolated lung transplantation in the United States according to the United Network for Organ Sharing (UNOS) thoracic transplantation Standard Transplant Analysis and Research data files between 1989 and 2012. Patients undergoing concomitant transplantation of any organ other than the lung were excluded, as were patients who did not survive transplantation and those who had incomplete/ missing records regarding our outcomes of interest or who did not have any follow-up data available (ie unable to match a transplant record to malignancy follow-up records in the UNOS databases).
Data definitions and primary outcomes
All available covariates captured in the UNOS database were analyzed, including demographic details, preoperative comorbidities, pretransplant hospitalization and operative details, donor-related details, and postoperative covariates. The primary outcome of our study was the occurrence of the first DNM after transplantation, defined as a malignancy diagnosed that the patient had no history of previously. The follow-up data were obtained from the UNOS thoracic transplantation malignancy follow-up database, and the date of first diagnosis of the DNM was available for time-to-event analyses (with patients censored at the time of death if this preceded DNM development). Patients who had or who developed an active malignancy while wait listed for transplantation were deemed ineligible to develop a DNM in our study. Malignancies were excluded from the count of DNMs if they were present in any form prior to transplantation, including if they developed while a patient was listed for transplantation or if the cancer was considered a reflection of metastatic disease. Additionally, squamous cell and basal cell carcinomas of the skin were not included in the final count of DNM; for the purposes of this paper, these cancers are excluded from the definition of DNM. Cancers were defined according to the International Classification of Diseases for Oncology (ICD-O-3)/World Health Organization (WHO) 2008 definitions (4, 5) . We also defined mortality after transplantation as a secondary outcome in order to determine the impact of DNM on survival after OLT; vital status along with last follow-up dates were taken from the UNOS thoracic transplantation database.
Statistical analysis STATA 12.0 was used to perform statistical analysis. Continuous variables were analyzed using Student's t-test or rank-sum tests according to distribution; categorical variables were analyzed with chi-squared tests. All p-values are two-sided, with statistical significance defined as a p < 0.05.
To make comparisons to a reference population, cancer types were classified according to the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. SIRs with corresponding 95% confidence intervals (CIs) were computed by comparing the observed incidence in our post-lung transplant population (as standardized by patient-years at risk of OLT patients) with the general population available through the SEER database. We utilized an exact method assuming observed DNM cases are Poisson distributed to compute 95% CIs for SIRs.
Unadjusted time-to-outcome analyses were analyzed using the method of Kaplan and Meier along with log-rank tests. Patients were censored at the time of last follow-up or death for the DNM outcome model and at the time of last follow-up for the mortality outcome model. To control for confounding, multivariable risk-adjusted Cox proportional hazards models were used to identify risk factors for both first DNM as well as mortality following OLT. All available covariates were first analyzed in univariable analyses against our two outcomes of interest, and those with a p < 0.20 were then entered manually forward into each outcome's multivariable model. No deviations from the proportional hazards assumption were noted on graphical testing. Model strength was assessed at the addition of each covariate using the Akaike information criterion and likelihood-ratio tests to construct the most parsimonious model possible by excluding variables that did not improve the model's strength based on these tests. Where clinically relevant, interactions between variables were tested as well.
Results
We identified a total of 23 991 isolated OLTs in the UNOS database between 1987 and 2012. After application of our exclusion criteria, we included the results of 18 093 patients operated on between 1989 and 2012. The 5898 excluded patients (24.6%) had insufficient follow-up data; 3052 (51.7%) of these excluded patients underwent OLT between 1987 and 1997. More than 75% of all available isolated OLT patients in the UNOS database were included between the years of 1997 and 2011; only 39.7% of patients from 2012 were included owing to limited follow-up.
Of the 18 093 included OLT patients followed for 75 600 patient-years, a total of 3154 malignancies developed in 2876 patients (15.9% of all patients). After excluding patients whose only DNMs were basal and/or squamous cell carcinoma of the skin, we identified 1388 DNMs in 1306 patients (2.8% of all patients) ( Table 1 ). The median time to first DNM diagnosis was 1142.5 days (interquartile range [IQR] 486-2099), and the first DNM diagnosed was a solid tumor in 71.6% (935) of patients developing any DNM, and lymphoproliferative disease/lymphoma in 21.3% (278). The 1-, 3-, and 5-year rates of developing a DNM were 1.4% (95% CI: 1.2-1.6%), 4.6% (95% CI: 4.3-5.0%) and 7.9% (95% CI: 7.4-8.4%). Of note, only six patients (0.4% of all patients developing a DNM) were diagnosed with a malignancy classified as "donorrelated" in the UNOS database (ie transmitted from a donor to recipient) (6, 7) . However, of 363 lung cancers observed, 57 occurred in patients receiving a bilateral OLT (15.8% of lung cancers), and 23 of these 57 were diagnosed within the first posttransplant year, suggesting that the true proportion of donor-related malignancies may be higher.
As compared with the general adult US population, malignancies were more commonly observed in OLT patients (SIR 3.26, 95% CI: 2.95-3.60, p < 0.001) ( As compared with OLT patients who did not develop a DNM, the 1306 DNM patients exhibited a number of statistically significant differences (Table 3 ). DNM patients were slightly older (55 AE 11 vs. 52 AE 13 years, p < 0.001), male (58.7% vs. 54.5%, p = 0.003) and of slightly greater body mass indices (25 AE 6 vs. 24 AE 6, p < 0.001). Smoking history was more common in DNM patients as well (75.5% vs. 65.7%, p < 0.001). Of note, a similar proportion of DNM and non-DNM patients had a history of prior malignancy (4.3% vs. 4.9%, p = 0.36). 
Bold type denotes total number of patients developing any non-SCC/BCC malignancy. BCC, basal cell carcinoma of the skin; IQR, interquartile range; SCC, squamous cell carcinoma of the skin. 
Discussion
In the present study, we found that DNMs other than skin squamous cell carcinoma (SCC)/basal cell carcinoma (BCC) occur in 4.6% and 7.9% of patients undergoing lung transplantation at 3 and 5 years posttransplant, respectively. These malignancies are approximately three times as common in OLT patients as compared with the general American population (SIR 3.26). The most commonly observed DNMs appear to be lung cancer and lymphoproliferative diseases, accounting for nearly half of all DNMs in the present study. Age, male gender, disease etiology and single-lung transplantation appear to be independently associated with DNM development. Variables independently associated with reduced survival include pretransplant functional status, single-lung transplantation, donor age, posttransplant dialysis and DNM development.
The incidences of various malignancies we observed correlate closely with data previously reported for a variety of posttransplantation patient populations (Table 6 ). In particular, SIRs and corresponding CIs for our Our multivariable Cox model to predict DNM development identified relatively few covariates associated with this outcome. Independent associations with DNM were documented only for increasing age, male gender, non-"other" disease etiologies (ie CF/IPF/COPD) and single-(vs. double-) lung transplantation. Perhaps equally notable was the lack of association between recipient or donor smoking history and DNM development after lung transplantation in our multivariable model to predict DNM development. This was a somewhat surprising finding particularly because lung cancers were the most common solid malignancies observed (excluding skin SCC/ BCC). Other authors have identified increasing age and smoking history as predictors of non-skin cancer malignancies after renal transplantation, in addition to immunosuppressive regimens, which our UNOS dataset did not address on follow-up (8-10). In heart transplant recipients, age, smoking history and treatment for rejection episodes have been associated with malignancy (11). Though we could not identify smoking as a risk factor for malignancy, we should note that this covariate could be analyzed only in binary fashion because pack-year histories were not contained in the dataset.
Though donor and recipient smoking history alone were not significantly independent predictors of DNM development or survival in our multivariable Cox model, we noted significant interactions between both of these variables and single-lung transplantation. These interactions, at least, are generally consistent with data emphasizing the role of smoking in metaplasia development after transplantation (12) . Because donors with heavy smoking histories have been shown to have worsened but still acceptable outcomes following lung transplantation (13, 14) , these concerns remain profoundly relevant.
Regarding the former interaction with recipient smoking history, these data are consistent with the observation that native lung malignancies account for the vast majority of lung cancers in recipients. Interestingly, though, we were only able to demonstrate a univariable, but not multivariable, interaction between disease type (eg IPF) and recipient or donor smoking history, which would be expected if smoking and IPF were to increase the risk of native lung DNM in concert. IPF was a significant predictor of DNM development on univariable analysis, consistent with previous findings (15, 16) . IPF did also interact significantly with single-lung transplantation to potentiate mortality, though not DNM development. One would expect that particularly IPF and perhaps COPD patients are at independently increased risk for DNM development, but our multivariable model simply showed that CF/IPF/COPD patients were at increased DNM risk, whereas "other" etiologies were at decreased risk. Our failure to establish the expected independent relationships, we believe, is due to a combination of sample size/missing data and our controlling for age, which may explain DNM development more powerfully than disease status or any other captured covariate. However, at the very least, if IPF is associated with cancer development, then it would stand to reason that DNM lung cancers arise in the native lung in patients transplanted with a single lung, which our data do suggest (ie single-lung transplantation was an independent predictor of DNM development). It should be noted that the excess risk of lung cancer was also observed in bilateral lung transplant recipients (SIR 2.29, 95% CI 1.59-3.28), raising the possibility that other processes unmeasured in our UNOS 
dataset-perhaps immunosuppressive regimens, though this is purely speculative-may contribute to lung malignancy in this patient population.
The interaction between donor smoking history and single-lung transplantation is intriguing, because we have limited data in the UNOS dataset to indicate that significant number of DNMs represent donor-derived malignancies. Remote induction of truly "new" DNMs by a smoking-exposed donor lung seems unlikely. It may be instead possible that such malignancies arising in the transplanted lung are not well captured in the database, or the effect may be due to other unobserved confounders. As noted, we documented 23 lung cancers arising in bilateral lung recipients in the first posttransplant year; these may be donor-related rather than true DNMs. Furthermore, it becomes even more difficult to clarify all of these confusing relationships when smoking dose information is unavailable.
We also noted some differences in our survival model as compared with a recent risk score for 1-year mortality derived by our group (17) . On multivariable analysis, we confirmed the importance of variables, including age, Karnofsky Performance Status score and increasing donor age. However, though we noted significant univariable associations between mortality and covariates for retransplantation, serum albumin <4 mg/dL, preoperative glomerular filtration rate (GFR), intensive care unit (ICU) and/or extracorporeal membrane oxygenation (ECMO) preoperatively, and recipient and donor cytomegalovirus (CMV) positivity, these variables all dropped out of the final multivariable model (ie did not contribute to model strength). Reasons for these observed differences may include that the risk score was derived only in patients transplanted between 2005 and 2012 as well as the limitation of that model to 1-year mortality. Of note, we did attempt to provide at least modest adjustment for trends in mortality over time by accounting for transplant year pre-versus post-2005, the year of Lung Allocation Score introduction. We were also forced to exclude patients missing adequate follow-up data, which likely affected our results.
Our study has several important limitations that are worth noting. First are the limitations inherent in a retrospective analysis. Additionally, though the relatively large sample size is a strength of the present study, one must be careful when utilizing large databases, particularly in regard to potential bias induced by missing data. We were forced to exclude nearly a quarter of OLT recipients over the study period because of missing or grossly incomplete follow-up data that precluded analysis of our endpoints, including a substantial proportion who underwent transplantation prior to 1997 and whose follow-up could be most valuable to an analysis of malignancy. Additionally, the median follow-up time of 1116 days limits our ability to address long-term trends in DNM development in this cohort. Finally, because the UNOS dataset does not capture details on immunosuppressive regimens on follow-up, we are unable to speculate about the undoubtedly critical role of these drugs in the evolution of DNMs. Lung transplant patients appear uniquely vulnerable to infection as well as rejection (ie bronchiolitis obliterans syndrome), and the interaction of these factors with immunosuppressive drug dosing over a patient's clinical course posttransplant undoubtedly affects DNM risk.
In conclusion, DNMs occur in 4.6% of OLT patients at 5 years posttransplant. OLT patients have about three times the risk for developing a wide range of solid malignancies as compared with the general American adult population, and this risk is particularly pronounced for lung and lymphoproliferative cancers. Increasing age, male gender, CF/IPF/COPD disease etiologies and singlelung transplantation appear independently associated with DNM development. Though neither recipient nor donor smoking history independently predicts DNM development, both appear to interact with single-lung transplantation to potentiate DNM development as well as mortality. After risk adjustment, DNM development is independently associated with mortality following OLT.
